```html

Isoniazid‑Induced Hepatotoxicity

---

Overview

Isoniazid‑induced hepatotoxicity is liver injury that occurs as an adverse reaction to the antituberculosis drug isoniazid (INH). Isoniazid is a cornerstone of both latent and active tuberculosis (TB) treatment, typically given for 6–9 months. While most patients tolerate the medication, up to 10–20 % of adults develop some degree of liver enzyme elevation, and 1–2 % experience clinically significant hepatitis that may require discontinuation of therapy.

The condition can affect anyone taking isoniazid, but certain groups are at higher risk, including:

• Adults over 35 years old (risk rises sharply after age 50)
• Patients with pre‑existing liver disease (e.g., hepatitis B/C, alcoholic liver disease)
• Those who consume regular alcohol or have a history of heavy drinking
• Patients receiving other hepatotoxic drugs simultaneously
• Genetic variations in the enzyme N‑acetyltransferase 2 (NAT2) that lead to “slow acetylators”

Globally, more than 10 million people receive isoniazid each year for TB control. Because of its widespread use, even a modest rate of hepatotoxicity translates into thousands of cases annually, making awareness essential for both patients and clinicians.

Symptoms

Liver injury from isoniazid can be silent (detected only by lab tests) or symptomatic. Common presenting features include:

• Fatigue or malaise – A vague sense of tiredness may precede other signs.
• Right upper‑quadrant (RUQ) abdominal discomfort – Dull or aching pain under the rib cage.
• Jaundice – Yellowing of the skin and whites of the eyes due to elevated bilirubin.
• Dark urine – Usually “tea‑colored” because of bilirubin excretion.
• Light‑colored stools – Due to reduced bile pigments reaching the intestines.
• Nausea or vomiting – May accompany RUQ pain.
• Anorexia or loss of appetite.
• Pruritus (itching) – Often associated with cholestasis.
• Fever – Uncommon but can occur with severe hepatitis.

Because many patients are asymptomatic, routine monitoring of liver enzymes (ALT, AST) is recommended during the first 2–3 months of therapy, when most cases develop.

Causes and Risk Factors

Mechanism of injury

Isoniazid is metabolized primarily in the liver by the enzyme N‑acetyltransferase 2 (NAT2). The process generates several metabolites, including acetylhydrazine and hydrazine, which are further oxidized by the cytochrome P450 system (mainly CYP2E1) into reactive radicals. These radicals can:

• Cause oxidative stress and lipid peroxidation of hepatocyte membranes.
• Deplete glutathione, the liver’s main antioxidant.
• Trigger an immune‑mediated response that damages liver cells.

Key risk factors

• Age ≥ 35 years – Incidence rises from 0.1 % in younger adults to >1 % after 50 years.
• Alcohol use – Even moderate intake (≥ 2 drinks/day) doubles the risk.
• Pre‑existing liver disease – Chronic hepatitis B or C, non‑alcoholic fatty liver disease (NAFLD).
• Genetic slow acetylator status – More common in certain ethnic groups (e.g., Caucasians, African‑Americans).
• Pregnancy – Hormonal changes may alter drug metabolism, though data are limited.
• Concomitant hepatotoxic medications – Rifampin, pyrazinamide, certain antiretrovirals, statins, methotrexate.

Diagnosis

Diagnosing isoniazid‑induced hepatotoxicity involves a combination of clinical assessment, laboratory testing, and exclusion of other causes.

Step‑by‑step approach

1. History & physical exam – Document timing of symptom onset relative to the start of isoniazid (usually 1–4 months), alcohol intake, and other drug exposures.
2. Liver enzyme panel –
   • ALT (alanine aminotransferase) and AST (aspartate aminotransferase) – Elevations > 3 × upper limit of normal (ULN) with symptoms or > 5 × ULN without symptoms suggest hepatotoxicity.
   • Alkaline phosphatase (ALP) – Helps differentiate cholestatic from hepatocellular injury.
   • Total bilirubin – Significant rise (> 2 mg/dL) or > 2 × baseline indicates clinically important injury.
3. Serologic tests to exclude other causes – Hepatitis A, B, C serologies; autoimmune markers (ANA, SMA); HIV test if risk present.
4. Imaging – Abdominal ultrasound is useful to rule out biliary obstruction or hepatic lesions.
5. Liver biopsy – Rarely needed; considered when diagnosis remains uncertain after non‑invasive work‑up.

According to the CDC’s TB treatment guidelines, isoniazid should be stopped if ALT/AST rise > 5 × ULN (asymptomatic) or > 3 × ULN with any hepatic symptoms.

Treatment Options

Management focuses on stopping the offending drug, supporting liver recovery, and completing TB therapy with alternative regimens.

Immediate actions

• Discontinue isoniazid as soon as significant hepatotoxicity is recognized.
• Hydration and nutrition – Adequate fluid intake and a balanced diet help liver regeneration.
• Monitor liver function – Repeat ALT/AST every 48–72 hours until levels trend down.

Pharmacologic support

• N‑acetylcysteine (NAC) – Antioxidant therapy shown to improve outcomes in acute drug‑induced liver injury; may be considered in severe cases (NASH 2014).
• Corticosteroids – Rarely used; only if an immune‑mediated component is strongly suspected.

Alternative TB regimens

If isoniazid must be stopped, a regimen that maintains efficacy against Mycobacterium tuberculosis is essential. Options include:

• Rifampin‑based 4‑month regimen – Rifampin + pyrazinamide (if tolerated) for 4 months (recommended by WHO for drug‑susceptible TB).
• Rifampin + ethambutol + fluoroquinolone – Used when both isoniazid and pyrazinamide are contraindicated.
• Short‑course regimens (e.g., 3‑month isoniazid‑rifapentine) – May be considered if hepatitis resolves quickly and the patient can be re‑challenged under close monitoring.

Re‑challenge (rare)

In selected patients who need isoniazid for latent TB treatment, a cautious re‑challenge at a lower dose (≤ 150 mg daily) with weekly liver tests may be attempted after full recovery, but only under specialist supervision.

Living with Isoniazid‑Induced Hepatotoxicity

Daily management tips

• Adhere to follow‑up labs – Keep all scheduled blood tests; even small elevations can herald worsening injury.
• Avoid alcohol completely while the liver is healing.
• Stay hydrated – Aim for at least 2 L of water per day unless contraindicated.
• Eat a liver‑friendly diet – Emphasize fruits, vegetables, whole grains, lean protein, and limit saturated fats, fried foods, and excess sugars.
• Medication checklist – Inform all healthcare providers that you had isoniazid‑related liver injury; carry a card listing the adverse reaction.
• Watch for symptom recurrence – New RUQ pain, yellow skin, or dark urine should prompt immediate lab testing.

Psychosocial considerations

Interrupting TB therapy can cause anxiety about disease control. Communicate openly with your TB specialist; most alternative regimens are equally effective and prevent the development of drug‑resistant TB.

Prevention

• Baseline screening – Obtain liver function tests before starting isoniazid, especially in patients > 35 years or with known liver disease.
• Risk‑stratified monitoring –
  • Every 2 weeks for the first 2 months in high‑risk patients.
  • Monthly thereafter for the remainder of therapy.
• Limit alcohol – Abstain or restrict to ≤ 1 drink/day for women and ≤ 2 drinks/day for men during treatment, ideally none.
• Consider alternative regimens for patients with known risk factors (e.g., use rifampin‑only prophylaxis for latent TB in slow acetylators).
• Genetic testing (optional) – NAT2 genotyping can identify slow acetylators; not routinely required but may guide decisions in specialized centers.
• Vaccination – Ensure hepatitis A and B immunity, reducing the chance of simultaneous viral hepatitis.

Complications

If hepatotoxicity is not recognized or treatment is delayed, several serious outcomes may occur:

• Acute liver failure (ALF) – Rapid loss of hepatic function leading to encephalopathy, coagulopathy, and need for transplant.
• Chronic hepatitis – Persistent inflammation that can progress to fibrosis or cirrhosis.
• Drug‑resistant TB – Incomplete therapy due to interruption increases the risk of resistant strains.
• Systemic complications – Renal failure, sepsis, or multiorgan dysfunction in severe ALF.

While mortality from isoniazid‑induced hepatitis is low (< 1 % in modern series), outcomes improve dramatically when the drug is stopped early and patients receive appropriate supportive care (Mayo Clinic).

When to Seek Emergency Care

---

Sources: CDC TB Treatment Guidelines (2022); WHO Consolidated Guidelines on Tuberculosis (2023); Mayo Clinic – Drug‑Induced Liver Injury; NIH LiverTox database; Cleveland Clinic – Isoniazid Hepatotoxicity; N‑acetylcysteine in Acute Liver Failure (NASH, 2014).

```